Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Pharmather Holdings Ltd PHRRF


Primary Symbol: C.PHRM

psychedelics
PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (CSE:PHRM)

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

GlobeNewswire 6 days ago

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

GlobeNewswire 9 days ago

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

GlobeNewswire April 2, 2024

PharmaTher's Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia

GlobeNewswire February 21, 2024

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

GlobeNewswire February 12, 2024

PharmaTher Provides Update for Expected FDA Approval of Ketamine

GlobeNewswire January 10, 2024

PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX(TM) (Ketamine)

GlobeNewswire September 27, 2023

PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX(TM) (Ketamine) to the FDA

GlobeNewswire September 6, 2023

PharmaTher Announces Positive Research Results for PharmaPatch(TM) with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics

GlobeNewswire July 18, 2023
View More News ››

Opinion & Analysis (CSE:PHRM)

No current opinion is available.
View More Opinion ››

Bullboard Posts (CSE:PHRM)

RE:RE:Why low-cost ketamine is still inaccessible to many...

For sure...thats how I see things here for PHRM. Short and long term, this company will be huge in valuation. Time will only tell of...
TheLandedEagles - 1 day ago

RE:Why low-cost ketamine is still inaccessible to many...

The article describes very well that ketamine can help in many areas of medicine, but that this fails due to regulations, among other...
BradlTheGerman - 1 day ago

Why low-cost ketamine is still inaccessible to many...

Why low-cost ketamine is still inaccessible to many with severe depression A case study on ketamine reveals systemic barriers that...
BradlTheGerman - 1 day ago

RE:RE:Only Up From Here!!!...FDA approval round the Corner!!!

Well...only God knows!!!...I dont give price predictions. Do know, in my opinion...PHRM, is drastically under valued today with its...
TheLandedEagles - 1 day ago

RE:Only Up From Here!!!...FDA approval round the Corner!!!

How high will it go?
Sailormark - 2 days ago

Only Up From Here!!!...FDA approval round the Corner!!!

Shortly we hear of FDA APPROVAL,..and suspect other great news announced of partnership with PHARMA's.  This company at this...
TheLandedEagles - 2 days ago
View more Bullboard ››

Q Precious & Battery Metals Corp

Q Precious & Battery Metals Corp

Q Precious & Battery Metals Corp., formerly Q Battery Metals Corp., is a diversified Canadian mineral exploration with ...
View More »